Castle Bioscience Buy of Cernostics Aligns With Goal to Diversify Portfolio
Genomeweb,
NEW YORK – Through its planned $80 million acquisition of Cernostics, Castle Biosciences aims to accelerate sales and marketing…
The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma
Overview of attention for article published in PLoS Currents, January 2013
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (92nd percentile)
-
Good Attention Score compared to outputs of the same age and source (71st percentile)
Readers on
- mendeley
- 53 Mendeley
